Spravato Safety Holds Up Long-Term for Treatment-Resistant Depression
NASHVILLE — Esketamine nasal spray (Spravato) showed consistent long-term safety outcomes for patients with treatment-resistant depression (TRD), according to follow-up data from the SUSTAIN-3 trial. In the open-label, phase III study, intermittent dosing of esketamine for up to 6.5 years had a similar safety profile as dosing for up to 1 year, according to Reina […]